Stockscreener 앱 받기
0.559
1.15%
-0.0065
시간 외 거래:
.57
0.011
+1.97%
전일 마감가:
$0.5655
열려 있는:
$0.56
하루 거래량:
212.38K
Relative Volume:
1.59
시가총액:
$21.64M
수익:
$7.88M
순이익/손실:
$-69.20M
주가수익비율:
-0.274
EPS:
-2.04
순현금흐름:
$-69.73M
1주 성능:
-12.11%
1개월 성능:
-10.76%
6개월 성능:
-29.50%
1년 성능:
-40.85%
1일 변동 폭
$0.5457
$0.5825
1주일 범위
$0.5457
$0.66
52주 변동 폭
$0.545
$1.56
볼트 바이오테라퓨틱스 Stock (BOLT) Company Profile
명칭
Bolt Biotherapeutics Inc
전화
650-665-9295
주소
900 CHESAPEAKE DRIVE, REDWOOD CITY
BOLT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| BOLT | 0.559 | 21.64M | 7.88M | -69.20M | -69.73M | -2.04 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
볼트 바이오테라퓨틱스 Stock (BOLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | 개시 | Guggenheim | Buy |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
볼트 바이오테라퓨틱스 주식(BOLT)의 최신 뉴스
HC Wainwright Issues Pessimistic Forecast for BOLT Earnings - Defense World
Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer Look - TipRanks
Bolt Biotherapeutics Reports Q3 2024 Financial Results - TipRanks
Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot - Houston Chronicle
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation - Yahoo Finance
BOLTBolt Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting - The Manila Times
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting - GlobeNewswire Inc.
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - Marketscreener.com
Bolt Biotherapeutics (STU:6LP) Cash Flow from Investing : €52.47 Mil (TTM As of Jun. 2024) - GuruFocus.com
Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
BOLT Stock Surges Over 5% Amidst Biotech Sector's Mixed Performa - GuruFocus.com
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline
Bolt Biotherapeutics (BOLT) Stock Surges Amid Broad Biotech Indu - GuruFocus.com
Renaissance Technologies LLC Sells 240,898 Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) - Defense World
Renaissance Technologies LLC Has $208,000 Stock Holdings in Hesai Group (NASDAQ:HSAI) - Defense World
Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Drops By 39.1% - Defense World
Just Auto Excellence Awards 2024: TomTom - just-auto.com
Bolt Biotherapeutics (BOLT) Stock Surges Amid Biotech Sector Vol - GuruFocus.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 14.2% in September - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.61 By Investing.com - Investing.com Canada
Bolt Biotherapeutics stock hits 52-week low at $0.61 - Investing.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Decrease in Short Interest - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.65 By Investing.com - Investing.com Australia
Bolt Biotherapeutics stock hits 52-week low at $0.65 - Investing.com
Bolt Biotherapeutics Announces Changes to its Board of Directors - ForexTV.com
Bolt Biotherapeutics reshuffles board, appoints new chair By Investing.com - Investing.com Canada
Bolt Biotherapeutics reshuffles board, appoints new director - Investing.com
Bolt Biotherapeutics Announces Board Reshuffle and New Appointment - TipRanks
Deadline on Sept. 3rd coming up in Lawsuit for Investors in shares of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) - openPR
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesBOLT - PR Newswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the - EIN News
BOLT Investors Have the Opportunity to Lead Bolt - GlobeNewswire
BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
BOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt - The Malaysian Reserve
BOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
BOLT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
BOLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt - GlobeNewswire
BOLT FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, - GlobeNewswire
Sept. 3rd Deadline ALERT: Investors Who Lost More Than $100,000 With Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shares Should Contact the Shareholders Foundation - Newswire
볼트 바이오테라퓨틱스 (BOLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):